

CONTENTS

Contents	Page
LIST OF FIGURES	I
LIST OF ABBREVEATIONS	II
LIST OF TABLES	III
INTRODUCTION	
Congestive heart failure.....	1
*control of normal cardiac contractility.....	1
*pathophysiology of heart failure.....	2
Beta adrenergic blocking drugs	7
*classification.....	7
Carvedilol.....	10
*chemical structure.....	11
*pharmacokinetics.....	11
*pharmacodynamics.....	14
*indications	14
*side effects.....	19
*contrindications.....	19
*drug interactions.....	21
Renin angiotensin system.....	25
*primary components of renin-angiotensin system ...	26
*renin	26
*angiotensinogen.....	28
*angiotensin converting enzyme.....	29
Angiotensin II receptors.....	31
*AT ₁ Biochemical signal pathways.....	32
*structure of AT ₁ subtype receptor.....	33
*functions of AT ₁ receptor subtypes.....	35
*AT ₂ binding site and biochemical signaling.....	35
*function of AT ₂ receptor subtype.....	35
The angiotensin II type I receptor antagonists.....	38
*discovery of angiotensin II receptor antagonists.....	40
*mechanism of action.....	41
*members.....	42
*pharmacokinetics.....	44
*effects.....	44

Valsartan.....	51
*Chemical structure.....	51
*pharmacokinetics.....	53
*pharmacodynamics.....	60
*indications.....	61
*side effects.....	61
*contraindications.....	61
*overdose.....	61
*drug interactions.....	62
Aim of the work.....	63
Material and methods.....	64
*in vitro experiments.....	64
*in vivo experiments.....	67
*statistical analysis.....	75
Results.....	76
*in vitro experiments.....	76
*in vivo experiments.....	89
Discussion.....	134
Summary and conclusion.....	158
References	161
Arabic summary.....	199

LIST OF FIGURES

Fig. No	Title	Page No.
(1)	Schematic diagram of a cardiac muscle sarcomere, with sites of action of several drugs that alter contractility.	2
(2)	Chemical structure of carvedilol	11
(3)	The components of the renin-angiotensin system.	26
(4)	Intracellular signal generation by angiotensin II in vascular smooth muscle cells.	33
(5)	Structure of AT ₁ receptors.	34
(6)	Renin-angiotensin system and its pharmacologic blockade.	40
(7)	Chemical structure of valsartan	51
(8)	A record showing the effect of different concentrations of methanol on (NE) and Ang II induced contractions of isolated rabbit aortic strip.	77
(9)	A figure demonstrating the interaction of carvedilol with norepinephrine on isolated rabbit aortic strip.	78
(10)	A figure demonstrating the interaction of valsartan with norepinephrine on isolated rabbit aortic strip.	78
(11)	a chart showing the effect of carvedilol and valsartan on norepinephrine induced contraction on isolated rabbit aortic strip.	80
(12)	A record showing the effect of carvedilol on the angiotensin II-induced contractions of isolated rabbit aortic strip.	81
(13)	A record showing the effect of valsartan on the angiotensin II –induced contractions of isolated rabbit aortic strip.	81
(14)	A chart showing the effect of carvedilol and valsartan on angiotensin II induced contraction on isolated rabbit aortic strip.	83
(15)	The effect of different concentrations of methanol on basal myocardial contractility of the isolated rabbit heart.	85

(16)	A record showing the effect of different doses of carvedilol on the amplitude of contraction of isolated rabbit heart.	86
(17)	A record showing the effect of different doses of valsartan on the amplitude of contraction of isolated rabbit heart.	86
(18)	chart showing the changes on mean amplitude of contraction of isolated rabbit heart after addition of carvedilol and valsartan in doses of 2, 4, 8, 16 and 32ug/ml.	88
(19)	A record showing the interaction of carvedilol with isoprenaline in rabbit heart.	89
(20)	A record showing the interaction of valsartan with angiotensin II in rabbit heart.	90
(21)	Blood pressure and ECG tracings of normal rat, recieved no isoprenaline injection.	92
(22)	Blood pressure and ECG tracings of heart failure group of rats recieved isoprenaline injection.	93
(23)	Blood pressure and ECG tracings of carvedilol treated group of heart failure.	94
(24)	Blood pressure and ECG tracings of valsartan treated group of heart failure.	95
(25)	Circular section of left ventricle of control group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, infarct tissue is pale.	96
(26)	Circular section of left ventricle of carvedilol group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, infarct tissue is pale.	97
(27)	Circular section of left ventricle of valsartan group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, infarct tissue is pale.	98
(28)	A charts showing the effects of carvedilol versus valsartan treatment on arterial blood pressure, heart rate and % surface area of infarct size.	100
(29)	Longitudinal cut section of rat heart of control group showing normal cardiac smooth muscle cells.	102

(30)	Longitudinal cut section of rat heart of H.F. group showing myocardial necrosis and interstitial fibrosis.	103
(31)	Longitudinal cut section of rats group treated with carvedilol showing less necrotic changes and less interstitial fibrosis bands.	104
(32)	Longitudinal cut section of rats group treated with valsartan showing less necrotic changes and interstitial fibrosis bands.	105
(33)	ECG tracing (lead II) of control rat received isoprenaline.	109
(34)	ECG tracing of pre-treated rat received carvedilol before isoprenaline injection.	110
(35)	ECG tracing (lead II) of pre-treated rat received valsartan before isoprenaline injection.	111
(36)	ECG tracing of post treated rat received carvedilol before isoprenaline injection.	112
(37)	ECG tracing of post treated rat received valsartan before isoprenaline injection.	113
(38)	A chart showing effect of carvedilol and valsartan treatment on mean \pm SE of T-wave voltage (mV) in pretreated and posttreated groups compared to control group.	115
(39)	A chart showing the effect of carvedilol and valsartan treatment on mean \pm SE of heart rate in pretreated and posttreated groups compared to control group.	117
(40)	A chart showing the effect of carvedilol and valsartan on serum CPK level (U/L) in pre-treated and post-treated groups compared to normal and control group.	121
(41)	Longitudinal cut section of rat heart of control group showing normal cardiac smooth muscle cells.	123
(42)	Longitudinal cut section of rat heart of acute myocardial infarction group showing myocardial necrosis and interstitial fibrosis.	124
(43)	Longitudinal cut section of rat pre-treated group with carvedilol showing less necrotic changes and less interstitial fibrosis bands.	125

(44)	Longitudinal cut section of rat post-treated group with carvedilol showing less necrotic changes and less interstitial fibrosis bands.	126
(45)	Longitudinal cut section of rat pre-treated group with valsartan showing less necrotic changes and interstitial fibrosis bands.	127
(46)	Longitudinal cut section of rat post-treated group with valsartan showing less necrotic changes and interstitial fibrosis bands.	128
(47)	Circular section of left ventricle of acute myocardial infarction group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, infarct tissue is pale.	131
(48)	Circular section of left ventricle of carvedilol pretreated group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, infarct tissue is pale.	132
(49)	Circular section of left ventricle of carvedilol posttreated group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, and infarct tissue is pale.	133
(50)	Circular section of left ventricle of valsartan pretreated group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, and infarct tissue is pale.	134
(51)	Circular section of left ventricle of valsartan posttreated group stained, by triphenyl tetrazolium chlorid stain, healthy tissue is stained chromosen red, and infarct tissue is pale.	135
(52)	A chart showing the effect of carvedilol treatment and valsartan on infarct size surface area represented as % of total surface area of the left ventricular segments in pretreated and post treated groups compared to control group.	137

LIST OF ABBREVIATIONS

ACEI	Angiotensin converting enzyme inhibitors
ADP	Adenosin diphosphate
AMP	Adenosine monophosphate
Ang II	Angiotensin II
AT₁	Angiotensin type 1 receptor
AT₂	Angiotensin type 2 receptor
AUC	Area under the curve
CHF	Congestive heart failure
C_{max}	Maxium plasma concentration.
CPK	Creatine phosphokinase
CYP450	Cytochrome oxidase
ECG	Electrocardiography mapping.
L-NAME	N-omega Nitro-L- arginine methyl ester.
MAP	Mean aortic pressure
NE	norepinephrine
NO	Nitric oxide
NYHA	New York Heart Association.
PAI-1	Plasminogen activator inhibitor-1
PRA	Plasma renin activity
RAS	Renin angiotensin system
SAP	Systolic aortic pressure
SE	Standard error
SHR	Spontaneous hypertensive rats.
SR	Sarcoplasmic reticulum
t_{1/2}	Plasma half life
TTC	Triphenyl tetrazolium chloride stain
U.S.	United State

LIST OF TABLES

Tab. No	Title	Page No.
(1)	Classification Criteria of AT Receptor Subtypes	31
(2)	Angiotensin II receptor subtypes: tissue distribution and functional correlates.	37
(3)	Members of angiotensin II receptor antagonists	43
(4)	Showing the effect of carvedilol versus valsartan on mean \pm SE amplitude of norepinphrine-induced contraction on isolated rabbit aortic strip.	79
(5)	Showing the effect of carvedilol versus valsartan on mean \pm SE amplitude of angiotensin II-induced contraction on isolated rabbit aortic strip.	82
(6)	Showing the effects of carvedilol and valsartan on mean \pm SE of amplitude of contraction of isolated rabbit heart.	87
(7)	Mean \pm SE of blood pressure (mmHg), heart rate (b/min.) and percentage surface area of infarct size.	99
(8)	Effect of carvedilol and valsartan on mean \pm SE of T-wave voltage (mV) in pretreated and posttreated groups compared to control group.	114
(9)	Effect of carvedilol and valsartan treatment on mean \pm SE of heart rate {b/min.} in pretreated and posttreated groups compared to control group.	116
(10)	Effect of carvedilol and valsartan treatment on mean \pm S.E of CPK values [U/L] in pretreated and post-treated groups compared to normal and control groups.	120